Pharma

Your Article Summary

See Latest Articles

Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkins Lymphoma
Cell Therapeutics, 10/23/09

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission in relapsed/refractory aggressive and indolent non–Hodgkin's lymphoma patients.

Today in Conferences/Meetings...keeping you current

Receive free subspecialty "5-minute updates" via email

ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
ImmunoGen, Inc., 11/25/09

AMA meeting: Nap time mandate for on-call residents rejected
American Medical News , 11/25/09

AMA meeting: Delegate vote refines AMA stance on system reform
American Medical News , 11/25/09

 See all of Conferences/Meetings

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09

Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09

Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09

 See all of Research & Development